Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25357358 | 0.77 | NLRP3 (0.48) | NLRP3PDGFRACDK5TYRO3MAPK8 | |
| SCHEMBL25360566 | 0.77 | NLRP3 (0.48) | NLRP3PDGFRACDK5TYRO3MAPK8 | |
| SCHEMBL25356861 | 0.74 | NLRP3 (0.57) | NLRP3PDGFRACDK5TYRO3MAPK8 | |
| SCHEMBL25036653 | 0.73 | NLRP3 (0.44) | NLRP3PDGFRACDK5TYRO3MAPK8 | |
| SCHEMBL498685 | 0.71 | NLRP3 (0.46) | NLRP3PDGFRACDK5TYRO3 | |
| SCHEMBL16596067 | 0.71 | GRM4 (0.43) | NLRP3PDGFRACDK5TYRO3MAPK8 | |
| SCHEMBL29492185 | 0.71 | NLRP3 (0.64) | NLRP3PDGFRACDK5TYRO3 | |
| SCHEMBL25356370 | 0.71 | NLRP3 (0.53) | NLRP3PDGFRACDK5TYRO3MAPK8 | |
| SCHEMBL13322761 | 0.70 | PDGFRA (0.55) | NLRP3PDGFRACDK5TYRO3CHEK1 | |
| SCHEMBL17839887 | 0.70 | NLRP3 (0.39) | NLRP3PDGFRACDK5TYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217346-B1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-02 | — | — | EP | disclosed |
| US-20230391756-A1 | NEW COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-07 | — | — | US | disclosed |
| EP-4217346-A1 | NEW COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| CN-116323585-A | New compounds | 詹森药业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022063876-A1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391756-A1 | NEW COMPOUND | NLRP3, NLRP1, IL1R1 | NLRP3 1/4885PDGFRA 4323/4885CDK5 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.